Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
María J Moro-Álvarez1, Manuel Díaz-Curiel21Hospital Central Cruz Roja, Madrid, 2Fundación Jiménez Díaz, Madrid, Spain, Internal Medicine, Metabolic Bone Disease UnitAbstract: Postmenopausal osteoporosis increases susceptibility to low...
Enregistré dans:
Auteurs principaux: | María J Moro-Álvarez, Manuel Díaz-Curiel |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2008
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/2c92af5d20584aba942b4444933a767c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
par: Paula Rackoff
Publié: (2009) -
Review of the safety and efficacy of risedronate for the treatment of male osteoporosis
par: Raja Bobba, et autres
Publié: (2007) -
Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
par: Irene Lambrinoudaki, et autres
Publié: (2008) -
Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
par: Philip Sambrook
Publié: (2007) -
Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice
par: Oliver Bock, et autres
Publié: (2008)